Publications

Annual review of immunology

Immune Niches in Cancer.

01-04-2026

Nature reviews. Immunology

Guidelines for T cell nomenclature.

01-04-2026

Journal of experimental & clinical cancer research : CR

Tertiary lymphoid structures in the era of cancer therapy.

11-02-2026

Communications biology

MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation.

22-01-2026

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Key Publication

Cell reports. Medicine

Voices: Future directions in targeting the tumor microenvironment.

18-11-2025

bioRxiv : the preprint server for biology

MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation.

21-07-2025

Journal for immunotherapy of cancer

SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.

25-06-2025

PloS one

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.

31-07-2024

Nature reviews. Cancer

Rational combination of cancer therapies with PD1 axis blockade.

30-07-2024

Cancer discovery

CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.

01-07-2024

Journal for immunotherapy of cancer

Mapping the complexity and diversity of tertiary lymphoid structures in primary and peritoneal metastatic gastric cancer.

01-07-2024

NPJ breast cancer

Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program.

24-04-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics.

16-02-2024

Cancer discovery

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

05-10-2023

Nature cancer

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

01-09-2023

Nature cancer

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

01-09-2023

STAR protocols

Protocol for ex vivo culture of patient-derived tumor fragments.

16-06-2023

Nature communications

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy.

02-02-2023

Cancer cell

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

09-01-2023

Nature reviews. Cancer

Tumour avatars to model patients' responses to immunotherapy.

01-12-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.

14-11-2022

Nature cancer

Keeping track of the T cells that matter.

01-09-2022

Science translational medicine

NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity.

13-07-2022

Immuno-oncology technology

Multimodal predictors for precision immunotherapy.

01-06-2022

Science translational medicine

Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.

27-04-2022

Science (New York, N.Y.)

Tertiary lymphoid structures in cancer.

07-01-2022

Nature chemical biology

Single-cell analysis of regions of interest (SCARI) using a photosensitive tag.

01-11-2021

Cancer immunology research

Supporting the Next Generation of Scientists to Lead Cancer Immunology Research.

01-11-2021

Cancer discovery

Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy.

01-10-2021

Nature medicine

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

01-07-2021

Immuno-oncology technology

Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform.

01-06-2021

Journal for immunotherapy of cancer

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach.

01-08-2020

Nature cancer

Publisher Correction: Long-distance modulation of bystander tumor cells by CD8⁺ T-cell-secreted IFN-γ.

01-07-2020

Journal for immunotherapy of cancer

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.

01-07-2020

Nature reviews. Cancer

CD8⁺ T cell states in human cancer: insights from single-cell analysis.

01-04-2020

Nature cancer

Long-distance modulation of bystander tumor cells by CD8⁺ T cell-secreted IFNγ.

01-03-2020

Clinical cancer research : an official journal of the American Association for Cancer Research

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.

15-05-2019

Immunity

The First Shall (Be) Last: Understanding Durable T Cell Responses in Immunotherapy.

15-01-2019

Histopathology

Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.

01-09-2018

Nature medicine

A transcriptionally and functionally distinct PD-1⁺ CD8⁺ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.

01-07-2018

Cancer cell

T Cell Dysfunction in Cancer.

09-04-2018

Immune Niches in Cancer.

Guidelines for T cell nomenclature.

Tertiary lymphoid structures in the era of cancer therapy.

MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation.

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Voices: Future directions in targeting the tumor microenvironment.

MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation.

SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.

Rational combination of cancer therapies with PD1 axis blockade.

CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.

Mapping the complexity and diversity of tertiary lymphoid structures in primary and peritoneal metastatic gastric cancer.

Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program.

A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics.

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Protocol for ex vivo culture of patient-derived tumor fragments.

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy.

IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

Tumour avatars to model patients' responses to immunotherapy.

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.

Keeping track of the T cells that matter.

NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity.

Multimodal predictors for precision immunotherapy.

Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.

Tertiary lymphoid structures in cancer.

Single-cell analysis of regions of interest (SCARI) using a photosensitive tag.

Supporting the Next Generation of Scientists to Lead Cancer Immunology Research.

Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy.

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform.

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach.

Publisher Correction: Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ.

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.

CD8+ T cell states in human cancer: insights from single-cell analysis.

Long-distance modulation of bystander tumor cells by CD8+ T cell-secreted IFNγ.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.

The First Shall (Be) Last: Understanding Durable T Cell Responses in Immunotherapy.

Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.

T Cell Dysfunction in Cancer.

This site uses cookies

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

Publisher Correction: Long-distance modulation of bystander tumor cells by CD8⁺ T-cell-secreted IFN-γ.

CD8⁺ T cell states in human cancer: insights from single-cell analysis.

Long-distance modulation of bystander tumor cells by CD8⁺ T cell-secreted IFNγ.

A transcriptionally and functionally distinct PD-1⁺ CD8⁺ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.